trial · primary record
Molgramostim
Autoimmune Pulmonary Alveolar Proteinosis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 164 |
| Primary completion | 2027-05-30 |
| Primary endpoint | Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24 |
| Registry ID | NCT04544293 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:11.646Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04544293
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.